Researchers examined the effect of APOE ε4, PTSD, and TBI on the prevalence of Alzheimer disease and related dementias in veterans of European and African ancestries.

Leqembi is a humanized IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

Researchers sought to examine the association between apathy and function longitudinally across dementia severity.

Researchers sought to analyze brain concentrations of vitamin D and assess whether there were any associations with cognitive and neuropathology outcomes.

In a meta-analysis, researchers estimated the prevalence of dementia in a centenarian and near-centenarian population and identified the risk and protective factors for dementia.

Researchers examined longitudinal changes in CSF Alzheimer disease biomarker among patients with normal cognition over an 11-year follow-up, on average.

Does midlife hypertension and HHcy play a role in increasing the risk for Alzheimer disease?

Researchers sought to assess racial and ethnic disparities in MRI markers of cerebrovascular disease and neurodegeneration in midlife and late life.

Researchers performed a MR analysis of large ethnically diverse genetic data to assess the casual relationship between telmisartan’s target and AD.

As people living with HIV begin to age, their risk of developing HIV-associated cognitive decline increases. A specific training program to help patients with HIV with speed of processing (SOP) may help stall those effects.

In a phase 3 trial, researchers examined the efficacy of lecanemab, a monoclonal antibody, in adults with early AD.

AXS-05 is an investigational agent consisting of a proprietary formulation of dextromethorphan and bupropion.

Researchers systematically reviewed and quantified the risk for dementia associated with psychotic disorders.

Researchers sought to evaluate whether treatment with PDE5 inhibitors was related to a reduced incidence of AD and related dementia compared with ERA in patients with pulmonary arterial hypertension.

In a cross-sectional study, researchers determined the prevalence of dementia and mild cognitive impairment in the US in 2016.

Researchers compared the efficacy of computerized training with Web-based cognitive games with computerized training with crossword puzzles among adults with MCI.

Researchers examined the effects of mobile-based cognitive interventions among community-dwelling older adults.

Researchers compared amyloid PET positivity among racial and ethnic groups with individuals with mild cognitive impairment or dementia.

Researchers sought to assess whether following conventional dietary recommendations or a modified Mediterranean diet are associated with a lower risk of developing dementia.

Researchers examined the relationship between gut microbiome composition and mild cognitive impairment in middle-aged and older adults.

In a Mendelian randomization study, researchers evaluated the association of genetic liability to autoimmune diseases with Alzheimer disease.

Researchers sought to examine correlates of changes in memory performance over a 3-year period, focusing on health, social determinants, and specifically, minority stress factors.

Cardiovascular and genetic risk factors may predict decreased brain volume in Alzheimer disease-specific brain regions in high-risk postmenopausal women.

Researchers sought to access whether there is an association between dementia diagnosis and a higher risk for suicide.

Researchers sought to investigate the efficacy and safety of crenezumab in patients with early AD with confirmed amyloid-beta pathology.

Researchers evaluated the rate of antibiotic prescription fills and use rates among older patients with dementia receiving homebound care.

Researchers sought to determine the effects of an oral health intervention on the oral microbiome and cognitive function of patients with mild AD and assess its influence on disease progression.

Researchers sought to assess the accuracy of a novel prediction model for death in older adults with dementia.

By identifying existing medications that may be repurposed for dementia, clinicians may be able to provide faster treatment for those in need.

In an observational retrospective study, researchers assessed the incidence of new-onset AD within 360 days following COVID-19 infection in patients aged 65 years or older.